Loading
Off-the-shelf cancer vaccines target antigens shared across patients, such as mutant KRAS or HER2 peptides, so they are made in advance rather than per person. Sipuleucel-T is still the only approved therapeutic cancer vaccine in the US; tolerance to self-antigens and weak past results hold them back.
KRAS-directed vaccines (ELI-002 7P, Elicio; mRNA-5671), shared neoantigen vaccines (Gritstone SLATE, discontinued), HER2 peptide vaccines, and tumour-lysate approaches. Sipuleucel-T (2010) remains the only approved therapeutic cancer vaccine in the US; BCG for bladder cancer is the oldest immunotherapy.
A pre-manufactured antigen (peptide, mRNA, viral vector, dendritic cell) is given with an adjuvant.
Algenpantucel-L was a whole-cell pancreatic cancer vaccine given after surgery; the phase 3 IMPRESS trial showed no survival benefit.
A personalised vaccine made from the patient's own immune cells and tumour. Its 20-year-old phase 3 trial reported longer survival, but the way the result was analysed has divided the field.
A ready-made vaccine against the seven commonest KRAS mutations, given after pancreatic cancer surgery. Its phase 2 missed the main goal in 2026 but showed signs of activity.
GI-6301 was a vaccine made from yeast carrying brachyury, the protein that chordomas depend on. Given with radiotherapy in a randomised trial it did not improve tumour responses.
A vaccine made from two viruses carrying the PSA gene, meant to teach the immune system to attack prostate cancer. The big trial found it did nothing at all.
Rindopepimut is a peptide vaccine against EGFRvIII, a mutant protein found only on some glioblastomas. After a phase 2 that beat historical controls, the 745-patient double-blind phase 3 ACT IV found no benefit in 2016, and tumours in both arms had lost EGFRvIII at recurrence, a lesson in antigen escape.
Sipuleucel-T was the first therapeutic cancer vaccine approved (2010): it lengthened survival in metastatic prostate cancer by about four months without shrinking tumours or lowering PSA.
Query for this technology: (TITLE:"shared antigen cancer vaccine" OR ABSTRACT:"shared antigen cancer vaccine" OR TITLE:"KRAS vaccine" OR ABSTRACT:"KRAS vaccine" OR TITLE:"off-the-shelf cancer vaccine" OR ABSTRACT:"off-the-shelf cancer vaccine"). Results are unfiltered search hits about Off-the-shelf cancer vaccines, not a curated reading list.
Shares TareBio, CureVac, Nykode Therapeutics, Nina Bhardwaj.
Shares Nina Bhardwaj, Nouscom, Vaccinate against the resistance mutation before it takes over, Shared splice-derived neoantigens as off-the-shelf vaccine targets.
Shares Algenpantucel-L, IMPRESS (algenpantucel-L), ECLIPSE (GVAX pancreas and CRS-207), AMPLIFY-7P.
Shares AMPLIFY-7P, ELI-002 7P, The undruggable drivers, Pancreatic cancer roadmap: from Whipple's operation to gemcitabine, FOLFIRINOX, adjuvant chemotherapy, PARP inhibition, KRAS inhibition, vaccines and the surveillance question.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/